Article Cite This: Bioconjugate Chem. XXXX, XXX, XXX−XXX
pubs.acs.org/bc
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition Honorine Lebraud,† Richard A. Noble,‡ Nicole Phillips,‡ Keisha Heam,† Juan Castro,† Yan Zhao,‡ David R. Newell,‡ John Lunec,‡ Stephen R. Wedge,*,‡ and Tom D. Heightman*,† †
Astex Pharmaceuticals, 436 Cambridge Science Park, Cambridge CB4 0QA, United Kingdom Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, United Kingdom
Downloaded via UNIV OF CONNECTICUT on June 17, 2018 at 07:38:46 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.
‡
S Supporting Information *
ABSTRACT: MDM2 is a key negative regulator of the p53 tumor suppressor. Direct binding of MDM2 to p53 represses the protein’s transcriptional activity and induces its polyubiquitination, targeting it for degradation by the proteasome. Consequently, small molecule inhibitors that antagonize MDM2-p53 binding, such as RG7388, have progressed into clinical development aiming to reactivate p53 function in TP53 wild-type tumors. Here, we describe the design, synthesis, and biological evaluation of a trans-cyclooctene tagged derivative of RG7388, RG7388-TCO, which showed high cellular potency and specificity for MDM2. The in-cell reaction of RG7388-TCO with a tetrazine-tagged BODIPY dye enabled fluorescence imaging of endogenous MDM2 in SJSA-1 and T778 tumor cells. RG7388-TCO was also used to pull down MDM2 by reaction with tetrazine-tagged agarose beads in SJSA-1 lysates. The data presented show that RG733-TCO enables precise imaging of MDM2 in cells and can permit a relative assessment of target engagement and MDM2-p53 antagonism in vitro.
■
INTRODUCTION The mouse double minute 2 (MDM2) protein is an E3 ubiquitin ligase proposed to interact with many proteins,1 the best characterized of which is its role as a crucial negative regulator of the tumor suppressor, p53. The MDM2-p53 interaction directly inhibits the transcriptional activity of p53 and can result in p53 ubiquitination leading to its subsequent degradation by the proteasome. Owing to the importance of p53 as a tumor suppressor, disruption of this axis is commonly observed in cancer.2 Loss of p53 function occurs frequently through TP53 mutation, found in half of all cancers,3 but also through alterations in regulatory pathways such as the overexpression of MDM2 in tumors with wild-type p53. To restore the p53 regulatory pathway in tumor cells, inhibitors of the MDM2-p53 interaction have been developed as anticancer agents, several of which are under evaluation in Phase I clinical trials for the treatment of various cancers including AML, lymphomas, and a range of solid tumors including liposarcomas.4 Among these inhibitors, AMG232, a piperidinone analogue (Figure 1A), demonstrated in vivo antitumor activity in a SJSA-1 osteosarcoma xenograft model5,6 and RG7388, a Nutlin derivative (Figure 2A), was shown to induce cell cycle arrest and apoptosis in a neuroblastoma cell line with wild-type p53.7,8 A number of fluorescent techniques have been utilized to date to improve our understanding of MDM2 function and its interactions with other proteins. Imaging of MDM2 has been achieved by using a fused MDM2-GFP protein9 and also using © XXXX American Chemical Society
a fused MDM2-tag protein (V5 or Myc) for antibody recognition.10 Although widely used, these techniques do suffer from drawbacks, including perturbations of the system under observation as they generally require overexpression of the fusion protein compared to endogenous protein levels11 and the large protein tag may interfere with interactions with other proteins. More recently, a small molecule fluorescent probe has been described with which to image MDM2.12 This method is predicted to perturb the MDM2 environment to a lesser extent as compared with a fusion protein. However, the introduction of a fluorescent group to a small molecule protein ligand can adversely affect its affinity and cell permeability. In this case, the fluorescent probe showed relatively weak binding to MDM2 (Ki 2.3 μM in FP bioassay) and required high concentration in imaging experiments (10 μM), increasing the risk of imaging nonspecific binding events. Visualization of MDM2 was also recently performed by using a set of clickable MDM2 probes based on 3-imidazolylindoles which were clicked, in cells, with fluorescently labeled dyes.13 After probe treatment, a predominantly nuclear localization was observed and target engagement of the probe was confirmed by colocalization with MDM2. The authors also quantified the target occupancy of several MDM2 inhibitors by imaging in competition mode (see Received: May 7, 2018 Revised: May 30, 2018 Published: May 31, 2018 A
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
Article
Bioconjugate Chemistry
Figure 1. A. Structures of AMG232 and AMG232-TCO, the designed probe with the linker and tag highlighted. B. Co-crystal structure of an analogue of AMG232 with MDM2 (PDB: 4OAS). The red arrow shows the extension site identified.
Figure 2. A. Structures of RG7388 and RG7388-TCO, designed from RG7388, with the linker and tag highlighted. B. Co-crystal structure of an analogue of RG7388 with MDM2 (PDB: 4LWV) showing the potential site for extension (red arrow).
ligands AMG232 and RG7388. Both probes were evaluated against MDM2 in both cell-free and cellular assays. The probe designed from RG7388, RG7388-TCO, showed potent MDM2 binding in cells and was selected for further investigation. MDM2 imaging was performed by click reaction of RG7388TCO with a turn-on BODIPY-tetrazine dye in the MDM2 gene amplified and overexpressing cell lines SJSA-1 and T778. Cellular engagement with MDM2 was also studied in a pulldown experiment, an orthogonal strategy to fluorescence imaging, by click reaction of the RG7388-TCO probe with Tz-tagged agarose beads.
below), in a high throughput setting to identify novel chemical leads. To gain further insights into MDM2 behavior upon inhibition, we aimed to develop a clickable MDM2 probe using bioorthogonal chemistry. A well designed tagged probe can be used for “click and play” experiments with range of suitably tagged reagents, for example, by clicking with a tagged fluorescent dye for imaging experiments (cellular localization) or with tagged agarose beads for protein enrichment experiments (target engagement). Click chemistry offers the advantage of introducing a relatively small, nonpolar clickable tag to the MDM2 inhibitor, minimizing the impact on its physicochemical properties. Among the several reactions developed to date, the Inverse Electron Demand Diels−Alder (IEDDA) cycloaddition, a reaction between a strained alkene and a tetrazine, is the fastest bioorthogonal reaction available to date.14,15 This reaction has been used successfully by Weissleder and collaborators to image several proteins.16−18 We report the design, synthesis, and biological activities of TCO-tagged chemical probes derived from the potent MDM2
■
RESULTS AND DISCUSSION Rational Design and Synthesis of MDM2 Chemical Probes. Chemical probes bearing a TCO group as a clickable tag for the IEDDA reaction were rationally designed based on the available crystal structures of MDM2 bound to small molecule inhibitors. Inhibitors of protein−protein interactions typically have high MW, cLogP, and PSA, bringing the risk that introduction of a TCO group might have a negative effect on B
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
Article
Bioconjugate Chemistry Table 1. Biological Evaluation of MDM2 TCO Probes and Key Compoundsa GI50 (μM) AMG232 AMG232-TCO RG7388 RG7388-TCO Clicked RG7388 BODIPY-Tz a
IC50 (μM)
SJSA-1
SN40R2
T778
p53 induction (μM)
0.00051b 0.0090b 28% @ 0.0003 μMd 66% @ 0.001 μMb 73% @ 0.001 μMd 61% @ 100 μMd
0.50c 2.2b 0.032e 0.088b -
27% @ 10 μMc 8.2b 8.8e 4.2b -
32c 56c -
0.048d 1.0b 0.013e 0.027b -
Geometric means. bn = 2. cn = 4. dn = 1. en > 10.
Figure 3. Inverse Electron Demand Diels−Alder cycloaddition between RG7388-TCO and BODIPY-Tz, forming Clicked RG7388 with nitrogen as the only byproduct.
with the parent compounds, AMG232 and RG7388, respectively (Table 1). Following the ELISA binding assay, the cellular activities of the two probes were assessed in SJSA-1 (amplified MDM2, wild-type p53) and SN40R2 (amplified MDM2, p53 mutant); a paired cell line harboring a p53 mutation that results in resistance to MDM2-p53 inhibitors in growth inhibition assays.20 AMG232-TCO demonstrated modest potency in both cell lines with only a 4-fold difference between SJSA-1 and SN40R2, suggesting potential off-target activity, which is highly undesirable for imaging experiments. In contrast, RG7388-TCO showed good cellular potency in SJSA1 cells with only a 2-fold dropoff compared to RG7388 and exhibited modest activity in SN40R2 cells (Table 1). The ∼50fold difference in potency between the two cell lines, suggested that potential off-target effects arising from RG7388-TCO would be unlikely at the concentrations used for further experiments. The induction of p53 following MDM2 inhibition was also measured in SJSA-1 cells. AMG232-TCO suffered a 20-fold loss of potency compared to AMG232 whereas RG7388-TCO showed a negligible loss of activity by comparison with RG7388 (Table 1). RG7388-TCO exhibited comparable potencies to its parent inhibitor across the cell-free ELISA binding and cellular assays and showed no sign of off-target activity consistent with the previously reported selectivity of RG7388.7 Hence RG7388-TCO was chosen for the imaging studies. For the imaging experiments, we decided to use BODIPY-Tz, a turn-on fluorescent dye.21 The fluorescence is triggered upon reaction of the tetrazine group with the TCO tag, therefore reducing residual fluorescence from unreacted dye. To ensure that BODIPY-Tz did not bind to MDM2 and therefore would not cause any interference in the imaging experiments, it was
their cellular permeability and solubility. We therefore decided to design our MDM2 probes from the known inhibitors AMG232 and RG7388 whose physicochemical properties would likely tolerate modifications (Table S1). To conserve the binding mode and minimize disruptive interactions between the inhibitor and MDM2, the TCO tag was oriented toward the solvent. The MDM2-inhibitor crystal structures were used to design the linkers that position the tag sufficiently far from the protein to avoid the inhibitor disassociating from the protein upon the click reaction. By studying the cocrystal structure of a close analogue of AMG232 with MDM2,6 the carboxylic acid was identified as a potential linker attachment site (Figure 1A). With the carboxy group facing the solvent, insertion of a linker and tag could be achieved with minimum perturbation of the binding interactions with MDM2, and with minimum synthetic efforts (Figure 1B) to produce AMG232-TCO (Scheme S1). For the design of the chemical probe derived from RG7388, we used the cocrystal structure of an analogue of RG7388 with MDM219 which revealed two possible sites for linker attachment: the carboxy and the methoxy groups (Figure 2B). As the carboxy group was suspected of forming important interactions with MDM2 required for activity, only the methoxy group of RG7388 was extended. In the design of RG7388-TCO, the methoxy moiety was replaced by an alkoxy group containing a linker and TCO tag (Figure 2A and Scheme S2). Biological Evaluation of MDM2 Chemical Probes. The two TCO tagged probes were assessed against MDM2 in cellfree ELISA binding assays and whole cell assays in order to evaluate the effects of the linker and TCO tag modifications on potency. In the ELISA binding assay, AMG232-TCO and RG7388-TCO showed only a minor loss of potency compared C
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
Article
Bioconjugate Chemistry
Figure 4. A. Immunoblots showing the induction of MDM2 and p53 expression in SJSA-1 cells treated with RG7388 or RG7388-TCO (0, 100, 1000 nM) for 4 h. GAPDH shown as a loading control. Representative blot of 2 independent experiments. B. MDM2 immunofluorescence in SJSA-1 cells treated with RG7388 or RG7388-TCO (0, 100, 1000 nM) for 4 h. Corrected nuclear fluorescence intensity was quantified and normalized to vehicle treated cells probed for MDM2 post fixation. Values represent mean + SEM of 3 independent experiments. SJSA-1 or T778 cells incubated with RG7388-TCO (1 μM, 4 h) were prepared for both MDM2 antibody and BODIPY-Tz (100 nM) staining post-fixation. C. Corrected nuclear fluorescence intensity was quantified and normalized to vehicle treated cells probed for MDM2 or BODIPY-Tz. D. The nuclei are shown in blue (DAPI channel), the fluorescence from the click reaction is shown in green (dye channel), and MDM2 protein shown in red (MDM2 channel). The merged image of the three channels is also shown (merge). Data are representative of two experimental replicates.
florescent dye. The reaction between RG7388-TCO and BODIPY-Tz (Figure 3) was studied by LC-MS. RG7388TCO and BODIPY-Tz were mixed in a 1:1.2 ratio, in DMSO, and the mixture was analyzed by LC-MS after 10 min. The spectra showed nearly complete formation of the clicked product, Clicked RG7388, as a mixture of isomers (Figure S1).
evaluated against MDM2 in the cell-free binding assay and showed negligible activity (Table 1). Bioorthogonal Reaction. As mentioned previously, the IEDDA offers many advantages for imaging applications with the most important being the high signal-to-noise ratio which can be further enhanced by the use of a clickable turn-on D
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
Article
Bioconjugate Chemistry
Figure 5. A. SJSA-1 cells were treated with RG7388-TCO (100 nM) for 1 h before the addition of RG7388 (0−1000 nM) for a further 3 h before assessing RG7388-TCO binding through the intensity of BODIPY-Tz signal. B. Corrected nuclear fluorescence intensity was quantified to determine the competition between RG7388 and RG7388-TCO in cells. The upper schematic indicates the incubation periods of RG7388-TCO (100 nM) or the indicated dose of RG7388. Values represent mean + SEM of 3 independent experiments. Two-way ANOVA (p ≤ 0.05 *, p ≤ 0.01 **, p ≤ 0.001 ***). C. Immunoblotting showing the level of MDM2 pulled down by RG7388-TCO. SJSA-1 cells were incubated with RG7388-TCO at different concentrations for 4 h. Following cell lysis, MDM2 was pulled down using tetrazine agarose beads. Both MDM2 bound to RG7388-TCO (bound fractions) and MDM2 unbound to RG7388-TCO (unbound fractions) were analyzed by Western Blot. Data shown is representative of at least 2 biological replicate experiments.
staining (Figure 4C). Nuclear MDM2 staining was colocalized with BODIPY-Tz bound to RG7388-TCO, consistent with target engagement in two MDM2-amplified cell lines (Figure 4D). Target Engagement in Cells through Competition. Preliminary imaging experiments showed that the level of BODIPY-Tz signal, but not MDM2 antibody staining, was reduced in cells coincubated with an excess of RG7388, consistent with competition between the parent compound and RG7388-TCO (Figure S2B). We therefore further investigated the ability of RG7388 to compete with RG7388-TCO for MDM2 binding in SJSA-1 cells using the BODIPY-Tz dye. Following preincubation with 100 nM of RG7388-TCO for 1 h, cells were coincubated for 3 h with a range of concentrations (100−1000 nM) of unlabeled RG7388 or the corresponding vehicle, before the addition of BODIPY-Tz. Co-incubation with RG7388 reduced the BODIPY-Tz fluorescence intensity produced with 100 nM RG7388-TCO alone in a dosedependent manner, with 100 nM RG7388 causing a 50% reduction in signal and 1000 nM resulting in a BODIPY-Tz signal barely above the intensity observed in cells incubated with DMSO vehicle (Figure 5A,B). We also examined the reverse sequence preincubating cells for 1 h with a range of RG7388 concentrations followed by coincubation with 100 nM of RG7388-TCO for 3 h. Under these conditions, control fluorescence values (without the addition of unlabeled RG7388) were slightly reduced in comparison to the previous
Clicked RG7388 was assessed against MDM2 in the cell-free binding assay (Table 1) and exhibited potencies similar to RG7388. The result confirmed that the click reaction did not significantly interfere with the binding to MDM2. Cellular Induction and Localization of MDM2 in Response to RG7388-TCO. Both RG7388 and RG7388TCO were assessed for their ability to induce the expression of MDM2 and p53. In keeping with the similar potency of RG7388 and RG7388-TCO in the cell-free binding assay, MDM2 and p53 protein expression in SJSA-1 cells increased in a comparable dose-dependent manner by both compounds after 4 h of treatment as measured by Western blot (Figure 4A). In addition, using an MDM2 antibody and a fluorescently labeled secondary antibody, equivalent nuclear induction of MDM2 was also confirmed by fluorescence microscopy in SJSA-1 cells, following treatment with corresponding concentrations of RG7388 or RG7388-TCO (Figure 4B and Figure S2A). Having validated our design for RG7388-TCO and shown that the click reaction between RG7388-TCO and BODIPY-Tz is essentially complete in vitro after 10 min, additional imaging experiments were conducted in SJSA-1 cells. To visualize the localization of MDM2, we compared the MDM2-antibody detection method with BODIPY-Tz fluorescence following the click reaction with RG7388-TCO. In cells incubated with RG7388-TCO, the increase in fluorescence relative to vehicle treated cells was comparable for either BODIPY-Tz or MDM2 E
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
Article
Bioconjugate Chemistry experimental format (Figure 5B; p = 0.047 by Student’s twotailed t-test). In addition, while the ability to reduce the RG7388-TCO derived BODIPY-Tz signal with increasing doses of RG7388 remained dose-dependent, there was a trend for the magnitude of apparent antagonism to be reduced with RG7388 doses of 250−1000 nM although this did not reach statistical significance (Figure 5B). The variance between data generated under the two experimental conditions is likely to reflect time- and concentration-dependent differences in MDM2 protein induction that accompany MDM2-p53 antagonism in cells, a dynamic increase in MDM2 protein concentration being induced as a consequence of a feedback mechanism in response to increasing levels of unconstrained p53 protein. By examining a 1 h preincubation with 0−1000 nM RG7388 followed by a 3 h RG7388-TCO incubation, the total incubation time with 100 nM RG7388-TCO is reduced by 25% (3 h versus 4 h), in comparison to experiments where a 1 h pretreatment of 100 nM RG7388-TCO was then followed by 3 h of concurrent RG7388 treatment. Hence, in the absence of RG3788 an experimental format involving a shorter total incubation time with RG7388-TCO may lead to a reduced BODIPY-Tz signal as less MDM2 protein induction occurs. Conversely, preincubation with 250−1000 nM RG7388 and a net increase in total RG7388 exposure during the experiment will be expected to lead to enhanced MDM2 induction, thereby accounting for a greater fluorescence signal being revealed by treatment with RG7388-TCO/BODIPY-Tz. To further explore the potential effect of MDM2-induction and its influence on measuring target engagement in cells with RG7388-TCO, we utilized the click chemistry approach for MDM2 protein enrichment (pull-down) experiments. Tz-biotin was first coupled to streptavidin agarose beads. SJSA-1 cells were then incubated for 4 h with RG7388-TCO at different concentrations and lysed. The lysates were incubated with the tetrazine-tagged agarose beads to allow pull-down of MDM2 bound to RG7388-TCO (Figure S3) and the recovered MDM2 was analyzed by immunoblotting. Analysis of the bound fractions (i.e., MDM2 bound to RG7388-TCO) revealed that the level of MDM2 intensified with increased concentration of RG7388-TCO (Figure 5C and Figure S4). However, the same trend was observed in the unbound fractions (Figure 5C and Figure S4). The inability to diminish unbound MDM2 with increasing concentrations of RG7388-TCO is concordant with a dose-dependent induction of MDM2, which results from p53-mediated activation of MDM2 transcription as a negative feedback mechanism.
duces a concentration- and time-dependency that needs to be considered carefully when attempting to quantify MDM2 engagement in cellular experiments. While such probes may be used under defined in vitro conditions to examine relative MDM2-p53 antagonism in cells, MDM2-induction may limit their use in the determination of absolute target engagement or utility in other applications, for example, in quantitation of MDM2-p53 antagonist activity ex vivo with longitudinal experimental sampling.
■
EXPERIMENTAL PROCEDURES Materials. SJSA-1 cells were purchased from A.T.C.C. SN40R2 cells were developed by J. Lunec. T778 cells were kindly provided by Dr. Florence Pedeutour, University of Nice Sophia Antipolis, France. The high capacity streptavidin agarose beads (20359) and the centrifuge columns (89868) were purchased from ThermoScientific. Biotin-PEG4-tetrazine was bought from Conju-Probe. BODIPY-Tz dye was synthesized following literature precedent.21 The NE-PER nuclear and cytoplasmic extraction reagents (78835) were purchased from ThermoScientific. MDM2 antibodies were purchased from R&D Systems (1244) and Calbiochem (OP46), the anti-actin antibody was obtained from Abcam (ab6276) and the PARP antibody was bought from Cell Signaling (9542). MSD multiarray assay system was purchased from Mesoscale (K150DBD). Methods. See Supporting Information.
■
ASSOCIATED CONTENT
S Supporting Information *
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.bioconjchem.8b00315. Experimental procedures for the synthesis of AMG232TCO and RG7388-TCO, enzymatic assay protocol for the determination of IC50 values, cellular assay protocols for the determination of GI50 and p53 induction values, protocols for the fluorescence imaging experiments, and procedures for the protein enrichment experiments. (PDF)
■
AUTHOR INFORMATION
Corresponding Authors
*E-mail:
[email protected]. *E-mail:
[email protected].
■
ORCID
CONCLUSIONS These studies indicate that a trans-cyclooctene tagged derivative of the MDM2-p53 antagonist RG7388 can be utilized, in conjunction with a tetrazine-tagged BODIPY dye, as a bioorthogonal probe to reveal the cellular localization of ligand-bound MDM2. Furthermore, the RG7388-TCO probe can be used to image competitive antagonism with unlabeled RG7388 in tumor cells. A similar approach has been reported recently with the purpose of developing assays for quantitation of target occupancy by MDM2-p53 antagonists.13 Our data reveal that the quantification of MDM2 with such probes and its application to measure MDM2-p53 antagonism are highly dependent upon the experimental conditions used. The induction of MDM2 protein as a feedback response to treatment with either MDM2-p53 antagonists or their derivatives designed as bioorthogonal imaging probes intro-
Tom D. Heightman: 0000-0002-9109-4748 Notes
The authors declare the following competing financial interest(s): HL, KH, JC and TH are employees of Astex Pharmaceuticals, which has a commercial interest in the development of MDM2 inhibitors.
■
ACKNOWLEDGMENTS The authors gratefully acknowledge the financial support of Cancer Research UK (Grant Reference C2115/A21421) and Astex Pharmaceuticals. The authors would like to thank Reach Separations, Nottingham, UK, for the SFC chiral purification of compound 4, and Charles River, Harlow, UK for the cellular data of MDM2 probes. The authors also thank Dr. Torren M. Peakman for the NMR characterizations of AMG232-TCO and F
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
Article
Bioconjugate Chemistry
(18) Reiner, T., Earley, S., Turetsky, A., and Weissleder, R. (2010) Bioorthogonal small-molecule ligands for PARP1 imaging in living cells. ChemBioChem 11, 2374−2377. (19) Zhang, Z., Chu, X. J., Liu, J. J., Ding, Q., Zhang, J., Bartkovitz, D., Jiang, N., Karnachi, P., So, S. S., Tovar, C., et al. (2014) Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development. ACS Med. Chem. Lett. 5, 124−127. (20) Drummond, C. J., Esfandiari, A., Liu, J., Lu, X., Hutton, C., Jackson, J., Bennaceur, K., Xu, Q., Makimanejavali, A. R., Del Bello, F., et al. (2016) TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Oncotarget 7, 46203−46218. (21) Carlson, J. C., Meimetis, L. G., Hilderbrand, S. A., and Weissleder, R. (2013) BODIPY-tetrazine derivatives as superbright bioorthogonal turn-on probes. Angew. Chem., Int. Ed. 52, 6917−6920.
RG7388-TCO, Stuart Whibley for his assistance with LC-MS studies and Dr. Gianni Chessari and Dr. Maria Ahn for helpful discussions.
■ ■
ABBREVIATIONS TCO, trans-cyclooctene; Tz, tetrazine; MW, molecular weight REFERENCES
(1) Fahraeus, R., and Olivares-Illana, V. (2014) MDM2’s social network. Oncogene 33, 4365−4376. (2) Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., and Lane, D. P. (2009) Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862−873. (3) Khoo, K. H., Verma, C. S., and Lane, D. P. (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discovery 13, 217−236. (4) Zhao, Y., Aguilar, A., Bernard, D., and Wang, S. (2015) Smallmolecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J. Med. Chem. 58, 1038−1052. (5) Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Mol. Cancer Ther. 14, 649−658. (6) Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57, 1454−1472. (7) Ding, Q., Zhang, Z., Liu, J. J., Jiang, N., Zhang, J., Ross, T. M., Chu, X. J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979−5983. (8) Chen, L., Rousseau, R. F., Middleton, S. A., Nichols, G. L., Newell, D. R., Lunec, J., and Tweddle, D. A. (2015) Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget 6, 10207−10221. (9) Di Stefano, V., Mattiussi, M., Sacchi, A., and D’Orazi, G. (2005) HIPK2 inhibits both MDM2 gene and protein by, respectively, p53dependent and independent regulations. FEBS Lett. 579, 5473−5480. (10) Schuster, K., Fan, L., and Harris, L. C. (2007) MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol. Cancer Res. 5, 403− 412. (11) Horisawa, K. (2014) Specific and quantitative labeling of biomolecules using click chemistry. Front. Physiol. 5, 457. (12) Liu, Z., Miao, Z., Li, J., Fang, K., Zhuang, C., Du, L., Sheng, C., and Li, M. (2015) A fluorescent probe for imaging p53-MDM2 protein-protein interaction. Chem. Biol. Drug Des. 85, 411−417. (13) D’Alessandro, P. L., Buschmann, N., Kaufmann, M., Furet, P., Baysang, F., Brunner, R., Marzinzik, A., Vorherr, T., Stachyra, T. M., Ottl, J., et al. (2016) Bioorthogonal Probes for the Study of MDM2p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery. Angew. Chem., Int. Ed. 55, 16026−16030. (14) Blackman, M. L., Royzen, M., and Fox, J. M. (2008) Tetrazine ligation: fast bioconjugation based on inverse-electron-demand DielsAlder reactivity. J. Am. Chem. Soc. 130, 13518−13519. (15) Devaraj, N. K., Weissleder, R., and Hilderbrand, S. A. (2008) Tetrazine-based cycloadditions: application to pretargeted live cell imaging. Bioconjugate Chem. 19, 2297−2299. (16) Yang, K. S., Budin, G., Reiner, T., Vinegoni, C., and Weissleder, R. (2012) Bioorthogonal imaging of aurora kinase A in live cells. Angew. Chem., Int. Ed. 51, 6598−6603. (17) Budin, G., Yang, K. S., Reiner, T., and Weissleder, R. (2011) Bioorthogonal probes for polo-like kinase 1 imaging and quantification. Angew. Chem., Int. Ed. 50, 9378−9381. G
DOI: 10.1021/acs.bioconjchem.8b00315 Bioconjugate Chem. XXXX, XXX, XXX−XXX
